Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 23341158)

Published in Ann Pharmacother on January 22, 2013

Authors

Lucas Hill1, Kelly C Lee

Author Affiliations

1: University of California, San Diego Medical Center, USA.

Articles citing this

Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health (2013) 1.01

Cognitive impairment in patients with AIDS - prevalence and severity. HIV AIDS (Auckl) (2015) 0.96

Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci (2013) 0.92

Disturbed Amino Acid Metabolism in HIV: Association with Neuropsychiatric Symptoms. Front Psychiatry (2015) 0.78

Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline. Antimicrob Agents Chemother (2014) 0.77

Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS. J Affect Disord (2017) 0.77

Managing drug interactions in HIV-infected adults with comorbid illness. CMAJ (2014) 0.75

HIV psychiatry in the era of combined antiretroviral therapy: top five issues. J Int AIDS Soc (2015) 0.75

Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment. Neurol Clin (2016) 0.75

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations. Antimicrob Agents Chemother (2015) 0.75

The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions. United European Gastroenterol J (2016) 0.75

Comparative effectiveness of dual vs single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. AIDS (2017) 0.75

Articles by these authors

Urine drug screening: practical guide for clinicians. Mayo Clin Proc (2008) 3.92

RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol (2004) 1.11

Clinical application of pharmacogenomics. J Pharm Pract (2012) 1.00

RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling. Oncogene (2004) 0.98

Institutional Profile: University of California San Diego Pharmacogenomics Education Program (PharmGenEd™): bridging the gap between science and practice. Pharmacogenomics (2011) 0.94

Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency. Psychiatr Serv (2009) 0.93

HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr (2010) 0.89

Development of a pharmacist-psychiatrist collaborative medication therapy management clinic. J Am Pharm Assoc (2003) (2012) 0.88

RACK1 inhibits the serum- and anchorage-independent growth of v-Src transformed cells. FEBS Lett (2004) 0.88

Navigating complex patients using an innovative tool: the MTM Spider Web. J Am Pharm Assoc (2003) (2013) 0.82

Implementation and outcomes of a live continuing education program on pharmacogenomics. Pharmacogenomics (2013) 0.80

Psychiatric pharmacist integration into the medical home. Prim Care Companion CNS Disord (2013) 0.78

A massive open online course on pharmacogenomics: not just disruptive innovation but a possible solution. Pharmacogenomics (2013) 0.78

A myoclonic reaction with low-dose hydromorphone. Ann Pharmacother (2006) 0.77

Nonparkinsonism movement disorders in the elderly. Consult Pharm (2006) 0.75

Dose-related paresthesias with venlafaxine. J Pharm Pract (2013) 0.75